Moreover, PTP-MEG2 inhibitor has shown to enhance Akt phosphorylation in primary hepatocytes and improve insulin resistance and glucose homeostasis in diet-induced obese C57BL/6 mice, suggesting that the inhibition of PTP-MEG2 activity may be a potential therapeutic approach in treating type 2 diabetes [1]. This evidence concerns the gene AKT1 and Insulin resistance.